Co-Diagnostics notes its technology to analyze self-administered coronavirus tests for Los Angeles school system

When the Los Angeles Unified school district starts testing its 700,000 students and 75,000 employees for the coronavirus (COVID-19), technology developed by Co-Diagnostics Inc (NASDAQ:CODX) will play a big role.  The nation’s 2nd-largest school system, which will start teaching online with the hope of eventual in-person instruction, will roll out the testing regime over the next few months.   The integrated testing program will be executed in part using Clinical Reference Laboratory (CRL), which recently received an Emergency Use Authorization from the US Food and Drug Administration (FDA) for a self-administered saliva test. That test will be analyzed using Co-Diagnostics’ technology. READ: Co-Diagnostics delivers $12.6 million profit in 2Q as demand for COVID-19 test kits propel stellar results Co-Diagnostics noted that CRL is one of the largest privately-held clinical testing laboratories in the US, with dedicated facilities in North America and Europe and staff of more than 600 associates working around-the-clock performing hundreds of thousands of tests every day for clients large and small. "We are pleased to see the protocol deemed necessary to keep our children safe has moved beyond masks, hand washing and social distancing, to include effective, robust testing and tracing,” Co-Diagnostics told Proactive said in a statement Tuesday.  “We believe that these elements form a vital part of any program to safely allow students in America to return to school. Tests for students and employees in the second-largest school district in the country will be performed using CRL processing expertise and Co-Diagnostics CoPrimer technology, without compromising turnaround speed or accuracy." In April, Co-Diagnostics received an Emergency Use Authorization from the FDA for its own COVID-19 tests. The Salt Lake City-based firm now has clients in more than 50 countries, including 25 US states, and validations of test accuracy from regulatory bodies of numerous countries around the world. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham